Impact of SGLT2 inhibitors in patients with Fabry disease
Treatment with SGLT2i of FD patients was safe and patients presented with stable disease courses. Especially males with reduced LVEF might benefit from SGLT2i treatment.
Authors
- Fabian Braun (ORCID: https://orcid.org/0000-0002-4742-050X)
- Nowak
- P Nordbeck
- Markus Cybulla (ORCID: https://orcid.org/0000-0001-7414-3096)
- Christine Kurschat (ORCID: https://orcid.org/0000-0002-3646-9471)
- G. Sunder-Plassmann
- Malte Lenders (ORCID: https://orcid.org/0000-0001-8409-2886)
- Constantin Gatterer (ORCID: https://orcid.org/0000-0003-1029-085X)
- Victoria Sokalski
- Eva Brand
- Christoph Wanner
- Sima Canaan-Kühl
Institutions
- Universität Hamburg (DE)
- University of Cologne (DE)
- University of Zurich (CH)
- University Hospital of Zurich (CH)
- Comprehensive Cancer Center Mainfranken (DE)
- University Hospital Münster (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer (DE)
- Medical University of Vienna (AT)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1007/s00392-026-02886-7
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Sanofi
- Alexion Pharmaceuticals
- Amicus Therapeutics
- Idorsia Pharmaceuticals